Innovent and Daiichi Sankyo sign deal for Vanflyta in China
Under the agreement, Daiichi Sankyo handles development and supply, while Innovent Biologics leads commercialisation in China.
Drug Development
Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs
Evotec and Odyssey collaborate on AI-enabled R&D
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
Alteogen signs $365m Hybrozyme licensing deal with pharma company
Schrödinger and BMS expand partnership to deploy AI for drug discovery
AsymBio to secure $184m to support growth in biologics manufacturing
Phylo and Chugai collaborate to deploy AI platform in drug discovery
